Evidence map›Paper›PMID 23223431›Full record

Trial reportBlood2013

High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Marlène Pasquet, Christine Bellanné-Chantelot, Suzanne Tavitian, Naïs Prade, Blandine Beaupain, Olivier Larochelle, Arnaud Petit, Pierre Rohrlich, Christophe Ferrand, Eric Van Den Neste and 10 more

Abstract readClinical Trial
In one paragraph

Trial report in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 1 pooled it
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 1 synthesis or guideline pooled it, 208 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Trial
  4. Trial
  5. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2014
    Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Pathogenic GATA2 genetic variants utilize an obligate enhancer mechanism to distort a multilineage differentiation program.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  19. Inborn Errors of Immunity and Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024
    Review
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 3 countries.

Marlène PasquetDepartment of Hematology, Centre Hospitalier Universitaire Toulouse Purpan, Toulouse, France.
Christine Bellanné-Chantelot
Suzanne Tavitian
Naïs Prade
Blandine Beaupain
Olivier Larochelle
Arnaud Petit
Pierre Rohrlich
Christophe Ferrand
Eric Van Den Neste
Hélène A Poirel
Thierry Lamy
Marie Ouachée-Chardin
Véronique Mansat-De Mas
Jill Corre
Christian Récher
Geneviève Plat
Françoise Bachelerie
Jean Donadieu
Eric Delabesse
Centre Hospitalier Universitaire de Toulouse · FRCentre de Recherche en Cancérologie de Toulouse · FRInserm · FRHôtel-Dieu de Québec · CACentre Hospitalier Universitaire de Rennes · FRCliniques Universitaires Saint-Luc · BEHôpital Armand-Trousseau · FRHôpital Robert-Debré · FRSorbonne Université · FRUCLouvain · BEUniversité de franche-comté · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

Severe Chronic Neutropenia International RegistryR24AI049393 · NIAID · UNIVERSITY OF WASHINGTON · PI DALE, DAVID CHANDLER · 2004 to 2019
$10.6M
6 · The paper itself

Abstract

unlabelledCongenital neutropenia is a group of genetic disorders that involve chronic neutropenia and susceptibility to infections. These neutropenias may be isolated or associated with immunologic defects or extra-hematopoietic manifestations. Complications may occur as infectious diseases, but also less frequently as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Recently, the transcription factor GATA2 has been identified as a new predisposing gene for familial AML/MDS. In the present study, we describe the initial identification by exome sequencing of a GATA2 R396Q mutation in a family with a history of chronic mild neutropenia evolving to AML and/or MDS. The subsequent analysis of the French Severe Chronic Neutropenia Registry allowed the identification of 6 additional pedigrees and 10 patients with 6 different and not previously reportedGATA2 mutations (R204X, E224X, R330X, A372T, M388V, and a complete deletion of the GATA2 locus). The frequent evolution to MDS and AML in these patients reveals the importance of screening GATA2 in chronic neutropenia associated with monocytopenia because of the frequent hematopoietic transformation, variable clinical expression at onset, and the need for aggressive therapy in patients with poor clinical outcome. KEY POINTS: Mutations of key transcription factor in myeloid malignancies.

Indexed as

Mutation, MissenseAdolescentAdultAmino Acid SubstitutionCell Transformation, NeoplasticChildChild, PreschoolFemaleFranceGATA2 Transcription FactorGenetic Diseases, InbornGenetic LociHumansLeukemia, Myeloid, AcuteMaleMyelodysplastic SyndromesGATA2 protein, humanGATA2 Transcription Factor

Identifiers

PMID23223431
PMCPMC3714670
OpenAlexW2060073480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.